drugset / Trial / NCT01166035
Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
Phase 1/2
Unknown
20 enrolled
Medical University Innsbruck
Celgene Corporation · collabInnsbruck - Tyrolean Working Group of Experimental Oncology (TEXO) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, monocentric, dose-escalation study of lenalidomide in combination with cetuximab in subjects with solid tumors. The primary objective is to establish the maximum tolerated dose (MTD) of lenalidomide in combination with cetuximab in patients with solid tumors including colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2010-03
- Primary completion
- 2011-09
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |